Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 202211013 | Other Grant/Funding Number | Jiangxi Provincial Health Commission |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Lin Zhou | UNKNOWN |
| Zhijun Chen | UNKNOWN |
| Yu Su | UNKNOWN |
| Jingxiu Zhong |
Not provided
Not provided
Not provided
Not provided
Clinincal data and pathological specimens from patients who had undergone at least one radioactive iodine-131 (^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected (approximately 30-50 cases each in the ^131I treatment-responsive group vs. the ^131I treatment-resistant group). Patients in the ^131I treatment-resistant group underwent ^18F-Trop2 PET-CT imaging.
Inclusion criteria:
Exclusion criteria:
Within the ^131I treatment-resistant group, comparisons were made between the rapidly progressing subgroup and the stable-disease subgroup under TSH-suppressive therapy in terms of clinicopathological features, tissue Trop2 expression levels, and SUVmax of metastatic lesions on ^18F-Trop2 PET-CT imaging. Factors influencing progression-free survival and overall survival in ^131I-resistant patients were analyzed.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RAI responder | The ¹³¹I treatment-responsive group was defined as patients who achieved successful radioactive iodine therapy (i.e., lesions disappeared or showed no long-term progression after radioiodine uptake). |
| |
| RAI nonresponder | The ¹³¹I treatment-resistant group was defined as patients meeting any of the following criteria: No radioiodine uptake in metastatic tissues during the first ¹³¹I treatment, with insignificant decrease or an increase in serum Tg levels before and after therapy; Partial lesions exhibit radioiodine uptake while others showed no uptaking; Progressive metastatic disease despite evident radioiodine uptake. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| radioiodine-131 therapy | Radiation | surgery, tsh inhibition therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Tumor size; | Lesion size was determined using CT imaging. Lymph nodes were assessed based on their shortest diameter, while other target lesions were evaluated based on their longest diameter. Each measurable lesion underwent an average measurement derived from a minimum of three readings, with all measurements conducted by the same individual to minimize measurement discrepancies. Response Evaluation Criteria in Solid Tumors (RECIST 1.1) were used to assess treatment response | 6-60 months |
| Measure | Description | Time Frame |
|---|---|---|
| Serological assessment | Including serum thyroglobulin (Tg) and serum anti-thyroglobulin antibody levels (TgAb) in thyrotropin-inhibited states, as well as tumor markers such as CEA | 1-60months |
Not provided
Inclusion Criteria:( 1) History of total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma (PTC); (2) At least one course of ^131I internal radiotherapy. Exclusion Criteria:(1) Presence of other severe comorbidities; (2) Incomplete clinical or follow-up data.
Not provided
Not provided
Not provided
patients who had undergone total thyroidectomy with postoperative pathology confirming papillary thyroid carcinoma and at least one radioactive iodine-131 (^131I) therapy in the Department of Nuclear Medicine at Jiangxi Cancer Hospital over the past 8-10 years were retrospectively collected
Not provided
| Name | Affiliation | Role |
|---|---|---|
| lin zhou | Jiangxi Provincial Cancer Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Jiangxi Cancer Hospital | Nanchang | Jiangxi | 330000 | China |
We will share our plan after our results be published
Not provided
Not provided
Not provided
Not provided
Not provided
| Tianzhu Lu | UNKNOWN |
Not provided
Not provided
Not provided
Postoperative paraffin-embedded specimens